Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Cerchietti Research Lab
Explore this Website
Home
Research
Toggle Research menu options
Projects
Lab Team
Publications
News
Weill Cornell Medicine
Care
Discover
Teach
Home
Research
Lab Team
Publications
News
Home
Publications
Publications
Found 18 results
Author
Title
Type
Year
Filters:
Author
is
Yang, Shao Ning
[Clear All Filters]
2021
M Calvo-Vidal N
,
Zamponi N
,
Krumsiek J
,
Stockslager MA
,
Revuelta MV
,
Phillip JM
,
Marullo R
,
Tikhonova E
,
Kotlov N
,
Patel J
et al.
. 2021.
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.
.
Cancer Res. 81(20):5202-5216.
2019
Fernando TM
,
Marullo R
,
Gresely BPera
,
Phillip JM
,
Yang SNing
,
Lundell-Smith G
,
Torregroza I
,
Ahn H
,
Evans T
,
Gyorffy B
et al.
. 2019.
BCL6 evolved to enable stress tolerance in vertebrates and is broadly required by cancer cells to adapt to stress.
.
Cancer Discov.
2017
Valls E
,
Lobry C
,
Geng H
,
Wang L
,
Cardenas M
,
Rivas M
,
Cerchietti L
,
Oh P
,
Yang SNing
,
Oswald E
et al.
. 2017.
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.
.
Cancer Discov.
Cayrol F
,
Praditsuktavorn P
,
Fernando TM
,
Kwiatkowski N
,
Marullo R
,
M Calvo-Vidal N
,
Phillip J
,
Pera B
,
Yang SNing
,
Takpradit K
et al.
. 2017.
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.
.
Nat Commun. 8:14290.
2016
Dupont T
,
Yang SNing
,
Patel J
,
Hatzi K
,
Malik A
,
Tam W
,
Martin P
,
Leonard J
,
Melnick A
,
Cerchietti L
. 2016.
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
.
Oncotarget. 7(3):3520-32.
Boi M
,
Todaro M
,
Vurchio V
,
Yang SNing
,
Moon J
,
Kwee I
,
Rinaldi A
,
Pan H
,
Crescenzo R
,
Cheng M
et al.
. 2016.
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
.
Oncotarget. 7(48):79637-79653.
2015
Tian YF
,
Ahn H
,
Schneider RS
,
Yang SNing
,
Roman-Gonzalez L
,
Melnick AM
,
Cerchietti L
,
Singh A
. 2015.
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
.
Biomaterials. 73:110-9.
Goldstein RL
,
Yang SNing
,
Taldone T
,
Chang B
,
Gerecitano J
,
Elenitoba-Johnson K
,
Shaknovich R
,
Tam W
,
Leonard JP
,
Chiosis G
et al.
. 2015.
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
.
J Clin Invest. 125(12):4559-71.
2013
Beguelin W
,
Popovic R
,
Teater M
,
Jiang Y
,
Bunting KL
,
Rosen M
,
Shen H
,
Yang SNing
,
Wang L
,
Ezponda T
et al.
. 2013.
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
.
Cancer Cell. 23(5):677-92.
Ruan J
,
Luo M
,
Wang C
,
Fan L
,
Yang SNing
,
Cardenas M
,
Geng H
,
Leonard JP
,
Melnick A
,
Cerchietti L
et al.
. 2013.
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
.
Blood. 121(26):5192-202.
2012
Fontan L
,
Yang C
,
Kabaleeswaran V
,
Volpon L
,
Osborne MJ
,
Beltran E
,
Garcia M
,
Cerchietti L
,
Shaknovich R
,
Yang SNing
et al.
. 2012.
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
.
Cancer Cell. 22(6):812-24.
2011
Shaknovich R
,
Cerchietti L
,
Tsikitas L
,
Kormaksson M
,
De S
,
Figueroa ME
,
Ballon G
,
Yang SNing
,
Weinhold N
,
Reimers M
et al.
. 2011.
DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.
.
Blood. 118(13):3559-69.
Cerchietti L
,
Damm-Welk C
,
Vater I
,
Klapper W
,
Harder L
,
Pott C
,
Yang SNing
,
Reiter A
,
Siebert R
,
Melnick A
et al.
. 2011.
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.
.
PLoS One. 6(4):e18436.
2010
Cerchietti LC
,
Hatzi K
,
Caldas-Lopes E
,
Yang SNing
,
Figueroa ME
,
Morin RD
,
Hirst M
,
Mendez L
,
Shaknovich R
,
Cole PA
et al.
. 2010.
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
.
J Clin Invest. 120(12):4569-82.
Cerchietti LC
,
Ghetu AF
,
Zhu X
,
Da Silva GF
,
Zhong S
,
Matthews M
,
Bunting KL
,
Polo JM
,
Farès C
,
Arrowsmith CH
et al.
. 2010.
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
.
Cancer Cell. 17(4):400-11.
2009
Ci W
,
Polo JM
,
Cerchietti L
,
Shaknovich R
,
Wang L
,
Yang SNing
,
Ye K
,
Farinha P
,
Horsman DE
,
Gascoyne RD
et al.
. 2009.
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
.
Blood. 113(22):5536-48.
Cerchietti LC
,
Yang SNing
,
Shaknovich R
,
Hatzi K
,
Polo JM
,
Chadburn A
,
Dowdy SF
,
Melnick A
. 2009.
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
.
Blood. 113(15):3397-405.
Cerchietti LC
,
Lopes EC
,
Yang SNing
,
Hatzi K
,
Bunting KL
,
Tsikitas LA
,
Mallik A
,
Robles AI
,
Walling J
,
Varticovski L
et al.
. 2009.
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
.
Nat Med. 15(12):1369-76.